Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis

Leukemia

Volumn 28, Issue 11, 2014, Pages 2257-2260

  Gordon, P M ^a,b   Dias, Stuart ^a   Williams, D A ^a  

^a HARVARD STEM CELL INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; STEM CELL FACTOR RECEPTOR;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; LEUKEMIA, MYELOID, ACUTE; MESENCHYMAL STROMA CELL; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL CULTURE;

APOPTOSIS; CYTOKINES; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MESENCHYMAL STROMAL CELLS; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR CELLS, CULTURED;

EID: 84922320222     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.212     Document Type: Letter

References (14)

1. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010; 115: 2372–2379. DOI: 10.1182/blood-2009-09-241075
2. Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Br J Haematol 2014; 164: 767–778. DOI: 10.1111/bjh.12725
3. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009; 12: 81–89. DOI: 10.1016/j.drup.2009.04.001
4. Beghini A, Bellini M, Magnani I, Colapietro P, Cairoli R, Morra E et al. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Exp Hematol 2005; 33: 682–688. DOI: 10.1016/j.exphem.2005.03.007
5. Mpakou VE, Kontsioti F, Papageorgiou S, Spathis A, Kottaridi C, Girkas K et al. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation. Leuk Res 2013; 37: 175–182. DOI: 10.1016/j.leukres.2012.10.011
6. Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012; 92: 1619–1649. DOI: 10.1152/physrev.00046.2011
7. Watari K, Asano S, Shirafuji N, Kodo H, Ozawa K, Takaku F et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989; 73: 117–122.
8. Cairo MS, Suen Y, Sender L, Gillan ER, Ho W, Plunkett JM et al. Circulating granulocyte colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation: endogenous G-CSF production correlates with myeloid engraftment. Blood 1992; 79: 1869–1873.
9. Kawakami M, Tsutsumi H, Kumakawa T, Abe H, Hirai M, Kurosawa S et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990; 76: 1962–1964.
10. Butterfield JH, Weiler DA, Hunt LW, Wynn SR, Roche PC. Purification of tryptase from a human mast cell line. J Leukoc Biol 1990; 47: 409–419. DOI: 10.1002/jlb.47.5.409
11. Watari K, Ozawa K, Tajika K, Tojo A, Tani K, Kamachi S et al. Production of human granulocyte colony stimulating factor by various kinds of stromal cells in vitro detected by enzyme immunoassay and in situ hybridization. Stem Cells 1994; 12: 416–423. DOI: 10.1002/stem.5530120409
12. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002; 2: 502–513. DOI: 10.1038/nrc840
13. Wang Y-Y, Zhou G-B, Yin T, Chen B, Shi J-Y, Liang W-X et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102: 1104–1109. DOI: 10.1073/pnas.0408831102
14. Wang Y-Y, Zhao L-J, Wu C-F, Liu P, Shi L, Liang Y et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011; 108: 2450–2455. DOI: 10.1073/pnas.1019625108